MAC Clinical Research and Kariya Pharmaceuticals are pleased to share the successful dosing of the first cohort in a phase 1 first-in-human (FIH) clinical trial of KP405, Kariya’s leading drug developed to slow the progression of Parkinson’s disease.
Dr John Connell, Chief Scientific Officer at MAC Clinical Research states ‘This is an exciting and significant milestone in the study of the Parkinson’s drug, KP405 which has been highly anticipated. We’re proud to be partnering with Kariya Pharmaceuticals in conducting this study and supporting them through their drug development journey in slowing the effects of Parkinson’s.’
The first-in-human (FIH) Phase 1 study is being conducted at MAC Clinical Research’s MHRA-accredited site in Manchester. The study will evaluate the safety, tolerability, pharmacokinetics (PK), and potential pharmacodynamics (PD) of both single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneously administered KP405 in healthy volunteers and Parkinson’s patients.
At MAC Clinical Research, we have a long and extensive history in CNS and neurodegenerative diseases with 72% of our studies falling within a CNS therapeutic area. We have conducted seven Parkinson’s Disease studies in the past five years. Our vast experience gives us an advantage in ensuring the successful and efficient delivery of this study.
Read the full press release issued by Kariya Pharmaceuticals here: https://www.linkedin.com/feed/update/urn:li:share:7218927292167647232/?actorCompanyId=13061909
